Cart
sales@molnova.com
Cyclosporin A-Derivative 1
CAS No. 1487360-85-9
Cyclosporin A-Derivative 1 ( )
Catalog No. M30543 CAS No. 1487360-85-9
Cyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 259 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameCyclosporin A-Derivative 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1.
-
DescriptionCyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. (In Vitro):Cyclosporin A-Derivative 1 is a non-immunosuppressive Cyclosporine A derivative. The cyclosporin is acylated on the butenyl-methyl-threonine side chain and then subjected to a ring-opening reaction (the ring opens between the sarcosine and the N-methyl-leucine residues). Cyclosporin A-Derivative 1 is a linear peptide intermediate.
-
Synonyms
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1487360-85-9
-
Formula Weight1364.5
-
Molecular FormulaC65H118BF4N11O14
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Fabrice Gallou, et al. Process for the manufacture of cyclic undecapeptides. WO 2013167703 A1.
molnova catalog
related products
-
Patrinia saponin H3
The herbs of Lonicera japonica Thunb.
-
Taurocholic acid
Taurocholic acid is a bile acid involved in the emulsification of fats.Taurocholic acid is cytoprotective, preventing tumor necrosis factor-alpha-induced cholangiocyte damage via a PI3K-mediated pathway.
-
PF-03814735
PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.
